Intest Res.  2019 Apr;17(2):273-277. 10.5217/ir.2018.00122.

Remission of diffuse ulcerative duodenitis in a patient with ulcerative colitis after infliximab therapy: a case study and review of the literature

• Choi YS
• Kim JK
• Kim WJ
• Kim MJ

• KMID: 2449969
• DOI: http://doi.org/10.5217/ir.2018.00122

Abstract

Although ulcerative colitis (UC) is confined to colonic and rectal mucosa in a continuous fashion, recent studies have also demonstrated the involvement of upper gastrointestinal tract as diagnostic endoscopy becomes more available and technically advanced. The pathogenesis of UC is not well established yet. It might be associated with an inappropriate response of host mucosal immune system to gut microflora. Although continuous and symmetric distribution of mucosal inflammation from rectum to colon is a typical pattern of UC, clinical feature and course of atypically distributed lesions in UC might also help us understand the pathogenesis of UC. Herein, we report a case of duodenal involvement of UC which successfully remitted after infliximab therapy. Endoscopic and pathologic findings before and after administration of anti-tumor necrosis factor suggest that the pathogenesis of upper gastrointestinal involvement of UC may be similar to that of colon involvement.

Keyword

Duodenitis; Colitis, ulcerative; Remission

MeSH Terms

Colitis, Ulcerative*
Colon
Duodenitis*
Endoscopy
Gastrointestinal Microbiome
Humans
Immune System
Inflammation
Infliximab*
Mucous Membrane
Necrosis
Rectum
Ulcer*
Upper Gastrointestinal Tract
Infliximab

Figure

• 

  Fig. 1. Endoscopic findings. (A) At initial colonoscopy, diffuse ulcerative inflammation with profuse exudation and spontaneous mucosal hemorrhage. (B) At 3 months follow-up colonoscopy after induction therapy with infliximab, mucosal healing showing whitish scar formation was noted. (C) At initial esophagogastroduodenoscopy (EGD), diffuse edematous and ulcerative inflammation on the bulb and 2nd portion of duodenum. (D) At 3 months follow-up EGD after infliximab induction therapy, endoscopic mucosal healing was achieved on the duodenal mucosa showing scar change.

• 

  Fig. 2. Histopathological findings. (A) High-power magnification of duodenum showing histologic features of chronic active duodenitis. There is a manifestation of chronic active colitis with crypt distortion, basal lymphoplasmacytosis and crypt abscess (H&E stain, ×200). (B) High-power magnification of duodenum after infliximab treatment. Note the decreased density of inflammatory cell infiltrates in lamina propria as well as decreased active inflammation compared to those of prior medical treatment. Instead of prominent inflammatory cell infiltrates, subepithelial fibrosis is also noted (H&E stain, ×200).

Reference

1. Mutinga ML, Odze RD, Wang HH, Hornick JL, Farraye FA. The clinical significance of right-sided colonic inflammation in patients with left-sided chronic ulcerative colitis. Inflamm Bowel Dis. 2004; 10:215–219.

2. Choi YS, Kim WJ, Kim JK, Kim DS, Lee DH. Efficacy of topical 5-aminosalicylate monotherapy in patients with ulcerative proctitis with skip inflammation. J Gastroenterol Hepatol. 2018; 33:1200–1206.

3. Ruuska T, Vaajalahti P, Arajärvi P, Mäki M. Prospective evaluation of upper gastrointestinal mucosal lesions in children with ulcerative colitis and Crohn’s disease. J Pediatr Gastroenterol Nutr. 1994; 19:181–186.

4. Kaufman SS, Vanderhoof JA, Young R, Perry D, Raynor SC, Mack DR. Gastroenteric inflammation in children with ulcerative colitis. Am J Gastroenterol. 1997; 92:1209–1212.

5. Mitomi H, Atari E, Uesugi H, et al. Distinctive diffuse duodenitis associated with ulcerative colitis. Dig Dis Sci. 1997; 42:684–693.

6. Thompson JW 3rd, Bargen JA. Ulcerative duodenitis and chronic ulcerative colitis: report of two cases. Gastroenterology. 1960; 38:452–455.

7. Valdez R, Appelman HD, Bronner MP, Greenson JK. Diffuse duodenitis associated with ulcerative colitis. Am J Surg Pathol. 2000; 24:1407–1413.

8. Terashima S, Hoshino Y, Kanzaki N, Kogure M, Gotoh M. Ulcerative duodenitis accompanying ulcerative colitis. J Clin Gastroenterol. 2001; 32:172–175.

9. Rubenstein J, Sherif A, Appelman H, Chey WD. Ulcerative colitis associated enteritis: is ulcerative colitis always confined to the colon? J Clin Gastroenterol. 2004; 38:46–51.

10. Kawai K, Watanabe T, Nakayama H, Roberts-Thomson I, Nagawa H. Images of interest. Gastrointestinal: small bowel inflammation and ulcerative colitis. J Gastroenterol Hepatol. 2005; 20:1791.

11. Hori K, Ikeuchi H, Nakano H, et al. Gastroduodenitis associated with ulcerative colitis. J Gastroenterol. 2008; 43:193–201.

12. Akitake R, Nakase H, Tamaoki M, Ueno S, Mikami S, Chiba T. Modulation of Th1/Th2 balance by infliximab rescues postoperative occurrence of small-intestinal inflammation associated with ulcerative colitis. Dig Dis Sci. 2010; 55:1781–1784.

13. Hisabe T, Matsui T, Miyaoka M, et al. Diagnosis and clinical course of ulcerative gastroduodenal lesion associated with ulcerative colitis: possible relationship with pouchitis. Dig Endosc. 2010; 22:268–274.

14. Lin J, McKenna BJ, Appelman HD. Morphologic findings in upper gastrointestinal biopsies of patients with ulcerative colitis: a controlled study. Am J Surg Pathol. 2010; 34:1672–1677.

15. Chiba M, Ono I, Wakamatsu H, Wada I, Suzuki K. Diffuse gastroduodenitis associated with ulcerative colitis: treatment by infliximab. Dig Endosc. 2013; 25:622–625.

16. Willington AJ, Taylor G, White J, Gearry RB. Gastrointestinal: ulcerative colitis-associated duodenitis. J Gastroenterol Hepatol. 2018; 33:973.

17. Byeon JS, Yang SK, Myung SJ, et al. Clinical course of distal ulcerative colitis in relation to appendiceal orifice inflammation status. Inflamm Bowel Dis. 2005; 11:366–371.

18. Naves JE, Lorenzo-Zúñiga V, Marín L, et al. Long-term outcome of patients with distal ulcerative colitis and inflammation of the appendiceal orifice. J Gastrointestin Liver Dis. 2011; 20:355–358.